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Introduction
Breast cancer is the most common cancer in women and 
a leading cause of cancer death worldwide. Management 
of breast cancer relies on the availability of robust clinical 
and pathological prognostic and predictive factors to 
guide patient decision making and the selection of 
treatment options. In early-stage breast cancer, where the 
use of systemic therapy has to be determined for every 
patient, the three main prognostic determinants used in 
routine practice are lymph node (LN) status, tumor size, 
and histological grade. Th  e Nottingham (Elston-Ellis) 
modi ﬁ     cation of the Scarﬀ  -Bloom-Richardson  grading 
system, also known as the Nottingham Grading System 
(NGS) [1], is the grading system recommended by 
various professional bodies internationally (World Health 
Organi  zation [WHO], American Joint Committee on 
Cancer [AJCC], European Union [EU], and the Royal 
College of Pathologists (UK RCPath) [2,3]).
Th   e prognostic relevance of NGS in breast cancer was 
initially demonstrated in 1991 [1] and has been validated 
subsequently in multiple independent studies [4-14]. 
Since NGS has independent but equally powerful prog-
nostic value, it has been combined with LN stage and 
tumor size to form prognostic indices: the Nottingham 
Prognostic Index (NPI) [15], which includes NGS and LN 
stage with equal weighting, and the Kalmar Prognostic 
Index [4], in which grade is given a higher-weighted 
value. Owing to the prognostic information provided by 
NGS, it has also been incorporated in algorithms (for 
example, Adjuvant! Online [16]) and guidelines (for 
example, the St. Gallen guidelines [17]) to determine the 
use of adjuvant chemotherapy. NGS provides a simple, 
inexpensive, and routinely applicable overview of the 
intrinsic biological characteristics and clinical behavior 
of tumors, adding important informa  tion to other 
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factors, such as tumor size and LN status.
Although the current well-established clinical and 
histological factors and some well-deﬁ  ned  biological 
factors (that is, hormone receptors and HER2 expression) 
show strong association with prognosis and outcome, 
there are increasing concerns that these variables are 
limited in their ability to capture the diversity of clinical 
behaviors of breast cancer and that they would not be 
suﬃ   cient to tailor the therapy to individual patients. In 
addition, the perceived subjective nature of histo  patho-
logical assessment of the morphological features such as 
tumor grade has increased these concerns. Th  e intro-
duction of high-throughput technologies that survey 
thousands of genes and their products in a single assay, 
coupled with powerful analytical tools, has opened up 
new avenues for classifying breast cancer into biologically 
and clinically distinct groups based on gene expression 
patterns [18,19] and DNA copy number alterations [20]. 
However, these expression proﬁ   ling studies have 
suggested that molecular tests could perform better than 
the traditional histopathology and may replace it as the 
‘gold standard’ for prognostication and prediction of 
response to therapy [21]. Recent studies leading to the 
development of the 21-gene recurrence score (trade 
name Oncotype DX; Genomic Health, Inc., Redwood 
City, CA, USA [22,23]) have highlighted the issue of sub-
jec  tivity associated with histological grading and called 
into question the utility of histological grade as a prog-
nostic tool. Regrettably, these results have been perceived 
as direct evidence that molecular tests provide an 
objective and reproducible assessment of prognostic 
features of estrogen receptor (ER)-positive breast cancers 
but that histopathological analyses are subjec  tive and not 
reproducible.
Molecular methods undoubtedly provide prognostic 
and predictive information and may help identify new 
therapeutic targets, and the interest in molecular classi-
ﬁ  ers and their potential application is perfectly under-
standable. However, it is important to understand their 
limitations and critically evaluate their role in improving 
breast cancer prognostication above and beyond the 
traditional variables in a practical and cost-eﬀ  ective way 
[24,25]. Th  e role of NGS as a simple and cost-eﬀ  ective 
method of assessment of tumor biology should not be 
neglected. It is also important to recognize that in 
countries with limited health resources, access to expen-
sive new technologies may not be possible but that 
eﬀ  ective cost-eﬃ   cient methods, such as routine histo-
patho  logical evaluation, are available for all [26]. In fact, 
there are numerous lines of evidence to suggest that these 
molecular tests complement rather than replace the 
traditional pathological variables, such as NGS, to deﬁ  ne 
the optimal therapy for patients with breast cancer.
Here, we present an overview of the current evidence 
of the signiﬁ  cance of breast cancer grading in view of the 
availability of an increasing number of potentially alter-
na  tive molecular prognostic tests. We present in a prag-
matic way a comparison between NGS and recent 
molecular prognostic tests, taking into account evidence-
based clinical and biological signiﬁ  cance, cost-eﬀ  ective-
ness, practicality of application in diﬀ  erent parts of the 
world, and the impact of this on future plans for improve-
ment in breast cancer prognostication and management.
What is histological grade?
Invasive carcinomas are morphologically subdivided 
accord  ing to their growth patterns and degree of 
diﬀ  erentiation, the latter of which reﬂ  ects how closely they 
resemble normal breast epithelial cells. Th   is subdivision is 
achieved by assessing histological type and histological 
grade, respectively. Although tumor type provides useful 
prognostic information, the majority (60% to 75%) of 
breast cancers have no special type of characteristics (that 
is, invasive ductal carcinoma of no special type, or NST); 
those special types that show distinct prognostic signiﬁ  -
cance are relatively uncommon. As a consequence, the role 
of histological typing in clinical management decision 
making is currently limited [27].
Histological tumor grade is based on the degree of 
diﬀ  erentiation of the tumor tissue. In breast cancer, it 
refers to the semi-quantitative evaluation of morpho-
logical characteristics and is a relatively simple and low-
cost method, requiring only adequately prepared 
hematoxylin-eosin-stained tumor tissue sections to be 
assessed by an appropriately trained pathologist using a 
standard protocol. NGS is based on the evaluation of 
three morphological features: (a) degree of tubule or 
gland formation, (b) nuclear pleomorphism, and (c) mito-
tic count (Figure 1). For details, see [1,2] and Supple-
mentary Information [28].
Histological grade and prognosis
Multiple independent studies have shown that NGS has 
prognostic value that is equivalent to that of LN status [29] 
and greater than that of tumor size [4,15]. In a large study, 
Henson and colleagues [14], who assessed survival rates of 
22,616 cases of breast cancer, demonstrated that patients 
with histological grade 1, stage II disease had the same 
survival as those with grade 3, stage I disease. Th  e  authors 
also found that patients with grade 1 tumors of less than 2 
cm in size had an excellent prognosis, with 99% 5-year 
survival, even when they presented with positive LN. 
Th  ese results are supported by a recent study from the 
Nottingham group [11], which included 2,219 operable 
breast cancer cases with long-term follow-up. Th  is  study 
has demonstrated that grade is an important determinant 
of breast cancer outcome and complemen  tary to LN stage 
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in diﬀ  erent LN stage categories. Th  ese results provide 
evidence that histological grade, when used in 
conjunction with LN stage, can improve the prediction of 
outcome for individual patients and support its inclusion 
and use in multifactorial indices such as the NPI and 
Adjuvant! Online. Similar long-term validation has been 
demonstrated in screen-detected breast cancer in the 
Swedish Two-County Trial, which demonstrated that 
tumor grade, LN status, and tumor size at the time of 
diagnosis have a lasting inﬂ   uence on subsequent 
survival [10].
Th   ere is compelling evidence to suggest that histo  logical 
grade can accurately predict tumor behavior, particularly 
in earlier small tumors (tumor, node, meta  stasis [TNM] 
stage pT1), more than other ‘time-dependent’ prognostic 
factors such as tumor size (pT1a, pT1b, and pT1c) 
[4,9,11,15]. Studies have also demonstrated that grade is 
an independent prognostic factor in speciﬁ  c subgroups 
of breast cancer, including ER-positive breast cancer 
patients who have not [30] or who have received 
neoadjuvant endocrine therapy [31] and patients with 
LN-negative [5,11,13,32] or -positive [7,11] breast cancer 
regardless of ER expression. Recently, Desmedt and 
colleagues [33] demonstrated that in the ER-positive/
HER2-negative tumors (n = 628), only histological grade 
and the proliferation module retained their association 
with relapse-free survival (RFS) in the multivariate 
analysis (hazard ratio [HR] = 2.00, 95% conﬁ  dence 
interval [CI] 1.18 to 3.37; P = 0.01). In the Nottingham 
series [11,34], histological grade was an independent 
predictor of RFS in the ER-positive/HER2-negative 
tumors (n = 1,077) (HR = 2.13, 95% CI 1.79 to 2.53; 
P  <0.0001). Similar associations between grade and 
survival were found in (a) the LN-negative subgroup 
(n = 797), who received only adjuvant hormone therapy 
(HR = 1.85, 95% CI 1.46 to 2.34; P <0.0001, with rates of 
10-year risk of relapse of 7% for grade 1, 14% for grade 2, 
and 31% for grade 3), and in (b) ER-positive tumors with 
small-volume LN metastasis (pN1; one to three LNs 
positive) (n = 316) (HR = 2.07, 95% CI 1.51 to 2.86; 
P <0.0001, with rates of 10-year risk of relapse of 5% for 
grade 1, 24% for grade 2, and 43% for grade 3) [11,34]. 
Th  erefore, histological grade can provide important 
prognostic information for clinically relevant subgroups 
in which the beneﬁ  t of chemotherapy is less certain (for 
example, LN-negative/ER-positive or in patients with 
low-volume LN metastatic disease).
We have noted, consistently with the biological and 
clinical roles of histological grade on breast cancer 
behavior, an important association between histological 
grade and pattern of survival. Akin to high-grade 
lymphoma, high-grade breast cancers tend to recur and 
metastasize early following diagnosis, typically within the 
ﬁ   rst 8 years; thereafter, breast cancer-related deaths 
decrease in frequency. Low-grade tumors tend to show a 
very good outcome, and few (if any) events occur; those 
that do occur, do so relatively late in the lifetime of the 
patients. Grade 2 tumors show an intermediate outcome 
during the early years of follow-up; however, on long-
term follow-up, they show an obvious trend for continued 
recurrence and impaired outcome in the long term 
[11,35] (Figure  2). In contrast, LN stage, which can 
provide information on the likelihood of death or survival 
after breast cancer, shows limited value in predicting the 
timescale of these events (Rakha EA, Ellis IO, 
unpublished data). Th  is important observation provides 
further insight into the appropriate management strate-
gies of patients with breast cancer. High-grade tumors, 
with their risk of early recurrence and death, require 
consideration for prompt use of adjuvant chemotherapy, 
whereas patients with grade 1 tumors, which are almost 
Figure 1. Histological grade of breast cancer as assessed by the Nottingham Grading System. (a) A well-diff  erentiated tumor (grade 1) that 
demonstrates high homology to the normal breast terminal duct lobular unit, tubule formation (>75%), a mild degree of nuclear pleomorphism, 
and low mitotic count. (b) A moderately diff  erentiated tumor (grade 2). (c) A poorly diff  erentiated (grade 3) tumor with a marked degree of cellular 
pleomorphism and frequent mitoses and no tubule formation (<10%).
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follow-up with or without a potentially less toxic systemic 
therapy (that is, endocrine therapy).
Histological grade: contentious issues
Despite the utility of histological grade as a prognostic 
factor for ER-positive disease, there are numerous issues 
that ought to be considered for the correct use of 
histological grade in the management of patients with 
breast cancer [36-39]. Th  ese issues are detailed in the 
following sections.
Grade and size
Th  e latest (7th edition) AJCC TNM staging system 
endorsed NGS, but grade was not included in calculating 
stage [40]. Th   e decision to exclude grade as an element in 
the TNM staging system, as stated previously [36], is 
based mainly on the possible interaction between tumor 
size and histological grade and, in particular, the lack of 
clear evidence for the role of grade in small tumors (pT1 
and pT2). It should be noted that two of the basic 
principles of breast cancer screening are that outcome of 
patients with small invasive cancers is good and adverse 
events are rare. Th  e  eﬀ  ect of all known prognostic factors 
will therefore be limited in such a patient group. 
However, despite this constraint, there are several lines of 
evidence that demonstrate the prognostic signiﬁ  cance of 
NGS in small tumors. Studies that examine the prog-
nostic signiﬁ  cance of grade in small tumors quoted in the 
AJCC article by Singletary and colleagues [36] show 
marked variations in outcome, follow-up times, and 
number of patients. Th   ere was also variation in the grad-
ing method used, and information on histological grade 
was obtained from systematic pathology review, whereas 
in others, information about grade was abstracted from 
pathology reports, medical records, or tumor registry 
databases. Th  ese  diﬀ  erences in grading systems and study 
design are expected to lead to diﬀ  erent results regarding 
the prognostic signiﬁ  cance not only of grade but also of 
other variables should they have been assessed. To 
conclude, although extracting consistent data on the 
prognostic signiﬁ  cance of grade from the diﬀ  erent studies 
cited in the AJCC review [36] is challenging, studies in 
which modern methods for histological grading were 
employed have shown that its utility is retained in small 
tumors [1,5,6,9,11,27,32,41-43]. With the shift that 
mammographic screening causes in stage distribution, 
this issue has become increasingly impor  tant, with a high 
proportion of tumors being T1N0M0 at diagnosis, 
thereby limiting the relevance of TNM staging in routine 
practice.
In the Nottingham series, development of recurrent 
disease following diagnosis of grade 1 breast cancer was 
infrequent, and when observed, the recurrent lesions 
were either higher-grade tumors or second primaries. 
Th  e number of patients with grade 1 tumors who 
developed distant metastasis or died without developing 
a second event of higher-grade tumor was limited (4%) 
[44]. Th   is observation implies that grade 1 breast cancer 
studies that do not include pathology review and 
evaluation of the second event are likely to overestimate 
the risk of adverse outcome.
Further justiﬁ  cation for the exclusion of grade from 
TNM [36] is that large tumors (pT3 and pT4) tend to be 
Figure 2. Relationship between histological grade and breast 
cancer-specifi  c survival. (a) In the old Nottingham series (1977 to 
1989), no systemic therapy was off  ered to the patients. Of the 1,816 
patients, 404 (17.7%) had grade 1 tumors (gray curve), 621 (36.2%) 
had grade 2 (blue curve), and 791 (46.1%) had grade 3 (black curve) 
(χ2 = 97.5, P <0.0001). (b) In the recent Nottingham series (1990 to 
2002), systemic therapy was off  ered to the patients according to 
Nottingham Prognostic Index and estrogen receptor expression 
as described previously [11]. Of the 3,579 patients, 677 (18.9%) had 
grade 1 tumors (gray curve), 1,383 (38.6%) had grade 2 (blue curve), 
and 1,519 (42.4%) had grade 3 (black curve) (χ2 = 195.5, P <0.0001). 
Analysis of grade 1 and 2 only showed statistical survival diff  erence 
(χ2 = 20.7, P <0.0001). Both series are consecutive and included 
estrogen receptor-positive and -negative and lymph node-negative 
and -positive cases [11,75,76].
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for adjuvant chemotherapy, irrespectively of tumor grade. 
Although a higher proportion of larger tumors are 
grade 3 [8,11], some forms of lower-grade breast cancer 
such as hormone receptor-positive, low-grade invasive 
lobular cancers frequently present as large mammo-
graphi  cally occult tumors and are responsive to hormone 
therapy. Furthermore, if tumor size/stage alone largely 
dictates an oncologist’s choice of treatment, an argument 
could be made, at least in many centers, for the 
irrelevance of other biological variables, including gene 
expression signatures such as Oncotype DX, 70-gene 
signature, 76-gene signature, and genomic grade index 
(GGI). Likewise, although NGS might have limited prog-
nostic value in HER2-positive and triple-negative cancers 
as most of these tumors are of high grade (grade 3) 
[30,33], these tumors also typically exhibit poor-prog-
nosis gene signatures [45]. In addition, molecular 
classiﬁ  ers such as Oncotype DX and GGI [33] and the 
MammaPrint (Agendia, Amsterdam, Th  e Netherlands), 
the last of which is recommended to all patients, have 
negligible discriminatory power in ER-negative disease 
[30,33].
Th   erefore, we believe that treatment decisions based on 
TNM staging system, which measures the anatomic 
extent of the tumor, can be improved by the addition of 
histological grade, which measures the intrinsic bio-
logical features of the tumor and reﬂ  ects the potential of 
a carcinoma to metastasize or cause death. Integration of 
histological grade into the relevant TNM staging system 
has been accepted for other common epithelial tumors 
such as adenocarcinoma of the prostate. As the prog-
nostic value of NGS has been proven in operable breast 
cancer (stages I and II), in which decisions about systemic 
therapy usage and its regimen need to be made, histo-
logical grade could be incorporated in the TNM system 
to improve its ability to stratify cases into risk-associated 
subcategories corresponding to grade so that chemo-
therapy can be potentially be avoided in low-risk groups 
and considered a high priority for patients in a high-risk 
category. Th  e maximum beneﬁ   t of grade assessment 
would be in the subgroup of patients with ER-positive, 
LN stage N0 or N1 disease. Th  e current evidence 
indicates that grading has limited value in advanced or 
metastatic breast cancer (stages III and VI) and grading is 
not expected to change treatment decisions and therefore 
need not be considered in these cases.
Grade and tumor type
Th   e prognostic value of histological grade has been docu-
mented in most tumor types, including invasive lobular 
carcinomas [46]. Medullary carcinoma might appear to 
be one subtype in which grading is less signiﬁ    cant. By 
deﬁ  nition, these tumors are of high histological grade 
(grade 3) but may have a more favorable prognosis than 
their histological grade would imply [38]. However, a 
recent study shows that medullary carcinomas account 
for less than 1% of breast cancers as a result of the strict 
criteria required for its recognition and that they do not 
have a prognosis signiﬁ  cantly diﬀ  erent than that of other 
forms of grade 3 ductal carcinoma with prominent 
inﬂ  am  mation [38]. Importantly, a recent study suggested 
that the 70-gene prognostic signature may also fail to 
provide prognostic stratiﬁ  cation of patients with some 
special types of breast cancer. Given that NGS has been 
shown to provide prognostically relevant information for 
invasive ductal carcinomas of NST and lobular carci-
nomas, which together account for greater than 80% of 
all breast cancers, the systematic inclusion of histological 
type in breast cancer routine synoptic reports is also 
advo cated.
Grading of needle core biopsy specimens
Current evidence suggests that histological grading can 
be assessed relatively reliably whereas other well-estab-
lished prognostic factors, such as vascular invasion and 
tumor size, cannot [47,48]. However, some cases may be 
upgraded when the excision specimen is analyzed follow-
ing grading of core biopsies (that is, grade I in the core 
biopsy and grade II in the excision specimen; 30% to 40%). 
On the other hand, a diagnosis of NGS grade III in a core 
biopsy is not commonly changed when the excision 
specimen is graded (5% to 8%). Importantly, changes from 
grade I in the core to grade III in the excision specimen 
and vice versa are very rare (0% to 1%) [47,48].
Selection of patients for neoadjuvant therapy requires 
that prognostic information be available from non-
operative diagnostic tumor samples. Amat and colleagues 
[49] reported that assessment of grade on needle core 
biopsy (NCB) is a strong predictive factor of response to 
induction chemotherapy in breast cancer, independently 
of the type of regimen used. Th  erefore, despite the 
limitations associated with the accuracy of grading core 
biopsies related to tumor sampling issues and visibility of 
mitotic ﬁ  gures [47,48], assessment of histological grade 
on NCB can provide information to support preoperative 
treatment decision making.
Reproducibility of histological grade
One of the reasons cited in the past for the reluctance to 
use grading in patient management decisions has been 
the perceived lack of reproducibility of the method. Th  is 
may be highlighted by the relatively wide variation in the 
proportion of each grade in published series. However, a 
substantial number of studies have reported better levels 
of inter- and intra-observer concordance [1,27,50-59] 
(Table 1). Th   e variation in the proportion of each grade 
reported in the diﬀ  erent studies can be explained by the 
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the patient cohorts, including age distribution, 
symptomatic versus screening popula  tion, early versus 
advanced breast cancer groups, and details of tissue 
ﬁ  xation. Grading is dependent on a high quality of tissue 
preservation. Suboptimal levels of tissue ﬁ  xation lead to 
disruption and loss of visibility of mitotic ﬁ  gures, one of 
the three variables assessed in NGS. Assessment of grade 
in poorly ﬁ   xed tissue will therefore introduce a bias 
leading to a reduction in the proportion of cases classiﬁ  ed 
as grade 3 [1,2,60].
Another important point to improve the inter-observer 
agreement rates is the introduction of guidelines for 
standardization of pre-analytical parameters, including 
tissue handling, ﬁ   xation, and preparation, and of the 
methods for tumor grading. Diﬀ  erences between centers 
can be attributed in many cases to diﬀ   erences in the 
quality of tissue preparation [2,61]. Critical evaluation of 
these issues and recommendations for good practice have 
been provided by professional organizations (that is, 
WHO, EU, UK RCPath, and the International Union 
Against Cancer [UICC]) [2]. Th   e use of rigorously opti-
mized and standardized methods in Nottingham has 
provided a high NGS reproducibility between grading of 
a recent series [11] and that of an old series published 
more than two decades ago from the same institution 
with a similar percentage of cases in each grade (Table 2). 
Signiﬁ   cant improvements in the consistency of histo-
logical grading have been observed on a national basis in 
the UK through the publication of guidelines with linked 
educational activity and associated external quality 
assurance (EQA) [51]. Th   ese guidelines provide not only 
information on histological grading methodology but 
also recommendations on the application of these 
methods and guidance on tissue handling. Adherence to 
these guidelines and participation in EQA are also 
expected to improve assessment of other important 
prognostic factors in breast cancer, such as lympho-
vascular invasion and immunohistochemical determina-
tion of other biomarkers. In addition, the current use of 
NGS is expected to provide consistency among diﬀ  erent 
studies in the future as evidenced from multiple studies 
from the Nottingham group and other institutions that 
endorse NGS [2,39,60,62]. However, despite the objective 
improvements that have been made to breast cancer 
grading methods, any assessment of morphological 
characteristics inevitably retains a subjective element and 
is heavily dependent on the pre-analytical parameters.
It should be noted that the degree of scrutiny of the 
inter-observer reproducibility histological grade has never 
been applied to molecular tests in current clinical use. A 
more detailed reproducibility study of the performance of 
gene expression studies has not been conducted as of yet. 
In fact, issues of reproducibility are well recognized in all 
forms of medical laboratory testing. Despite the 
undeniable need to improve the inter-observer agree  ment 
for histological grade, the criticisms directed against NGS 
should be tempered by the fact that other parameters used 
to determine the therapy of patients with breast cancer 
also suﬀ  er from inter-observer variability, including the 
assessment of small-volume nodal metastases (LN stage), 
HER2 immunohisto  chemical and in situ hybridization 
scoring, ER scoring, assessment of vascular invasion, and 
even the assessment of tumor size.
Signifi  cance of grade 2 tumors
Mis-assignments of grade I to grade III or vice versa are 
rarely reported, but grade II tumors usually show the 
Table 1. Inter-observer and intra-observer agreement of breast cancer histological grade.
Study  Number of cases  Number of readers  Grade  Inter-observer
[32] 613  2  NGS  Kappa  0.69
[8] 52  2  NGS  Kappa  0.54
[55]  425  2  NGS  Complete agreement 76%
[50]  75  6  NGS  Kappa 0.43 to 0.74
[51]  12  600  NGS  Kappa 0.45 to 0.53 (fi  gures after application of guidelines)
[52]    3  NGS  Complete agreement 72.3%; kappa 0.57
[53]  24  21  NGS  Complete agreement 69%; kappa 0.53
[54]  50  5  NGS  Mean polychoric correlation 0.8
[56]  35  13  NGS  Kappa 0.5 to 0.7
[57] 93  7  NGS  Kappa  0.54
[58]  40  3  NGS  Kappa 0.68 to 0.83
[59]  874  2  WHO criteria  Complete agreement 78.1%; kappa 0.66
[61]  50  5  NGS  Complete agreement 83.3%; kappa 0.73
NGS, Nottingham Grading System; WHO, World Health Organization.
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phenomenon of scoring of a biological variable where 
scores in the overlap regions are usually most diﬃ   cult to 
be categorised. Th  e similar example of the problem of 
repro ducibility  of  classiﬁ  cation of a continuous biological 
variable was noted in the microarray-based gene expres-
sion proﬁ  ling studies [63,64]. For example, in the studies 
by Sorlie and colleagues [18] and Chang and colleagues 
[65], only a propor  tion of cases could be accurately 
classiﬁ   ed into the molecular subtypes, 9% to 15% of 
tumors could not be assigned as grade 1 and grade 3 by 
GGI [66], and 19% to 24% of cases showed discordance 
among diﬀ  erent gene expression signatures applied to the 
same set of tumors [45].
In the latest meeting of the St. Gallen International 
Expert Consensus on the Primary Th   erapy of Early Breast 
Cancer (2009) [17], it was recommended that grade 1 and 
grade 3 be taken into consideration for the assessment of 
indications of adjuvant chemotherapy. Grade 2 was 
regarded as being similar to other parameters of 
intermediate-risk signiﬁ   cance, such as tumor size of 
between 2 and 5 cm, low numbers (one to three) of 
involved LNs, and intermediate scores on multigene 
assays, and it was inferred that they do not provide a 
deﬁ  nitive indication of risk with respect to the clinical 
decision of whether to give or withhold chemo  therapy. 
However, it was also noted that the presence of these 
intermediate-risk criteria usually tips the balance toward 
the use of chemotherapy [17].
Th  e advantage of applications of molecular tests as 
complements to grade is particularly evident with respect 
to grade 2 tumors. Several attempts have been made to 
improve biological and clinical signiﬁ  cance of histological 
grading by classifying grade 2 tumors into two distinct 
subclasses: a grade 1-like subgroup, which has an 
excellent outcome and may not require adjuvant chemo-
therapy, and a grade 3-like subgroup, which comprises 
tumors that behave in a way similar to high-grade cancers 
and need a more aggressive systemic treatment. 
Examples of these studies include the application of GGI 
to subclassify histological grade 2 into two molecular 
subclasses (GGI1 and GGI3) [66] or the use of prolifera-
tion biomarkers such as MIB1 (Ki67) expression (Rakha 
EA, Ellis IO, unpublished data). However, the clinical 
useful  ness and the cost-beneﬁ   t ratios of these studies 
need to be further evaluated if they are to be translated 
into routine practice worldwide, particularly in countries 
with limited resources.
Grade and molecular profi  ling
Recent proﬁ  ling studies of breast cancer have emphasized 
the relevance of tumor biology in governing breast cancer 
behavior and hence the importance of histological grade. 
Tumors of diﬀ   erent histological grades show distinct 
molecular proﬁ  les at the genomic, transcriptomic, and 
immuno  histochemical levels. Th  ese results suggest that 
the majority of high-grade tumors are unlikely to stem 
from the progression of low-grade cancers and that grade 
1 and 3 breast tumors are probably diﬀ  erent diseases [67].
Gene expression studies have demonstrated that 
histological grade better reﬂ  ects the molecular makeup 
of breast cancer than LN status and tumor size do [68,69]. 
Sotiriou and colleagues [66] developed a 97-gene 
classiﬁ  er that can accurately identify cases diagnosed as 
NGS I or NGS III. Th   eir studies have shown an asso  cia-
tion between a ‘gene signature’ developed to recapitulate 
Table 2. Proportion of grades among diff  erent studies.
Study  Number of cases  Grade 1  Grade 2  Grade 3
Elston, 1984 [77]  625  17%  37%  46%
Davis et al., 1986 [78]  1,537  22%  49%  29%
Hopton et al., 1989 [59]  874  29%  46%  25%
Le Doussal et al., 1989 [79]  1,262  11%  45%  46%
Balslev et al., 1994 [80]  9,149  32%  49%  19%
Saimura et al., 1999 [5]  741  19  37%  44%
Reed et al., 2000 [32]  613  25%  41%  35%
Simpson et al., 2000 [7]  368  22%  45%  33%
Lundin et al., 2001 [6]  1,554  26%  47%  27%
Frkovic-Grazio and Bracko, 2002 [9]  270  38%  38%  24%
Warwick et al., 2004 [10]  1,988  23%  37%  40%
Williams et al., 2006 [26]  1,058  20%  46%  34%
Rakha et al., 2008 [11]  2,219  18%  36%  46%
Thomas et al., 2009 [81]  1,650  26%  45%  29%
Blamey et al., 2009 [12]  16,944  29%  41%  30%
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outcome, indepen  dently of LN status or tumor size [66]. 
Th  is assay is currently being commercialized in Europe 
(MapQuant Dx; Ipsogen, Marseille, France). When the 
prognostic performance of GGI was compared with the 
Oncotype DX [22] and 70- and 76-gene signatures, a 
similar separation in distant metastasis-free survival 
between low- and high-risk groups by the three 
signatures was found [45]. Another group has similarly 
demonstrated that the genetic grade signature (RNA-
based) remained signiﬁ   cantly associated with disease 
recurrence in most cases.
However, recent meta-analyses of microarray-based 
expression proﬁ  ling studies have demonstrated that the 
prognostic impact of the signatures investigated stems 
from the proliferation-related genes [30,33]. In fact, when 
several of the published signatures were divided into 
partial signatures composed of proliferation-related genes 
and genes not related to proliferation, the latter failed to 
show prognostic signiﬁ   cance, whereas the prog  nostic 
power of some signatures even improved by the removal of 
genes not related to proliferation [30]. Most importantly, 
in numerous studies using molecular signatures, 
histological grade remained an independent prognostic 
factor for ER-positive tumors even after the inclusion of 
gene signatures in the multivariate models [22,25].
Th   ere are several lines of evidence to suggest that the 
objective contribution of gene signatures above and 
beyond the current clinicopathological parameters is 
limited. Dunkler and colleagues [70] demonstrated that 
the explained variation of prognosis (that is, the 
proportion of patients whose prognosis is determined 
solely by a given parameter) by prognostic signatures is 
limited (for example, 3% for the 70-gene signature) when 
grade and other clinicopathological variables such as LN 
stage, patient age, and ER status are included in the 
survival models [30,70,71]. It is important to mention, 
however, that there are relatively few head-to-head 
compari  sons of NGS versus molecular signatures and 
that most of them so far have a competitive tone to them. 
Studies that combine molecular assays and NGS in a 
balanced manner would be warranted.
Grade in the era of molecular profi  ling tests
Prognostic molecular tests for patients with breast 
cancer, including Oncotype DX [22] and MammaPrint 
[72], have already been approved for clinical use. 
Undoubtedly, these assays support breast cancer prog-
nos  tication and can be used as a complement to the well-
established variables currently used in routine practice 
[73], as recently recommended in the St. Gallen guide-
lines [17].
Th  e cost of MammaPrint and Oncotype DX [74] is 
orders of magnitude higher than that of histological 
grading. Oncotype DX has undergone health economic 
evaluation in the US and has been reported to be cost-
beneﬁ   cial through reduction of widespread use and 
appropriate targeting of use of adjuvant chemotherapy. In 
countries or centers where chemotherapy is less widely 
prescribed or where targeting is based on other tests, 
there may be a reduced beneﬁ  t and justiﬁ  cation of the 
test cost [26]. Th   ere is a trend in the research community 
not to consider cost-eﬀ  ectiveness when promoting the 
use of a newly developed molecular test, even though 
costs typically are taken into consideration when 
evaluating new interventions [26,74]. Th   e costs of these 
modern assays are likely to remain high, and it should be 
borne in mind that there are still many parts of the world 
that do not and will not have ready access to these costly 
tests. Th  erefore, histological grading, when carried out 
properly on well-ﬁ   xed specimens, provides a simple, 
inexpensive, and highly accurate alternative method for 
assessing tumor biological characteristics and patient 
prognosis and identifying patients at high and low risk 
for adverse outcomes. In addition, the cost and availa-
bility are not the only factors limiting the routine 
applicability of currently approved or recommended 
molecular prognostic assays as there may also be some 
skepticism of the scientiﬁ  c rigor of industry-sponsored 
cost-beneﬁ  t economic models.
Given that grade has been shown by multiple indepen-
dent groups to be prognostic and that the levels of inter-
observer agreement have increased with the adoption of 
NGS, it is rather surprising that clinical practice has 
changed with molecular tests that have not been as 
comprehensively tested but has not changed with NGS. 
Possibly, this stems from the purported objectivity of 
molecular tests and the denounced subjectivity of 
histopathological analysis [25]. However, molecular tests 
also suﬀ  er from subjectivity in terms of the biostatistical 
approaches employed, the stability of the molecular 
subgroups identi  ﬁ  ed by the tests, and the reproducibility 
of assays performed with cell extracts without careful 
micro  dissection of tumor cells (that is, contamination 
with normal breast epithelial cells or proliferating stromal 
cells may change the results of molecular tests based on 
the assessment of ER- and proliferation-related genes) 
[25]. Th  erefore, it should be recognized that both 
molecular assays and NGS have their own strengths and 
weak  nesses, which vary in diﬀ  erent situations. Both can 
provide valuable prognostic information and both should 
complement rather than compete with each other and 
this should be understood when they are used for patient 
management decision making. When used in combi  na-
tion, molecular tests such as GGI are potentially impor-
tant in the subclassiﬁ  cation of grade 2 breast tumors. 
However, the application of molecular tests to known 
grade 1 and grade 3 breast cancers in the treatment 
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conﬁ  rmation of any additional prognostic value and cost 
beneﬁ  t.
Conclusions
Th   ere is an international consensus that NGS should be 
considered the ‘gold standard’ for breast cancer grading. 
Th  e adoption of the objective criteria of NGS has been 
shown to overcome many of the previous problems of 
reproducibility of grading, problems that resulted from 
using a variety of approaches. To provide a consistent 
and uniform way of assessing histological grade and to 
improve its reproducibility, consensus criteria and 
guidelines have been published with critical evaluation of 
these issues and recommendations for good practice [2]. 
Strict adherence to these criteria is expected to improve 
consistency and reproducibility of breast cancer grading 
among diﬀ  erent institutions. Histological grading, when 
adequately carried out, provides a simple, inexpensive, 
and highly accurate method for assessing tumor bio-
logical characteristics and patient prognosis. Th  is is of 
particular importance for breast cancer patients in parts 
of the world where access to new molecular technology is 
not currently available. Molecular assays and NGS should 
complement rather than compete with each other. We 
conclude that the assessment of histological grade is an 
important determinant of breast cancer prognostication 
and should be incorporated in staging systems and in 
algorithms to deﬁ   ne therapy for patients with breast 
cancer.
Take-home messages
Th   e Nottingham Grading System, when adequately 
carried out, provides a simple, inexpensive, accurate, and 
validated method for assessing patient prognosis.
Consensus criteria for histological grading and recom-
mendations for good practice have been published [2,51] 
and should be followed.
Th   e Nottingham Grading System is a validated 
alternative to molecular tests in parts of the world where 
access to new molecular technology is not currently 
available or likely to become available in the near future.
Assessment of histological grade is an important 
determinant of breast cancer prognostication and should 
be incorporated in algorithms to deﬁ   ne therapy for 
patients with breast cancer.
Search strategy and selection criteria
Literature databases, including PubMed, Medline, and 
the Cochrane Library, were searched for articles 
published from 1980 to 2009 in English. Th  e keywords 
used for the search were ‘breast cancer’, ‘grade’, ‘histo-
logic(al) grade’, ‘molecular proﬁ  le’, and ‘reproducibility’ in 
relation to biology, prognosis, prediction, and patient 
outcome. Articles published before 1980 or in another 
language were also considered if they were commonly 
referenced or were highly regarded older publications. 
Th  e search also included the references list for these 
articles and selected additional articles and webpages 
that were judged to be relevant. Data from publications 
submitted as abstracts were excluded.
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